Gujarat Themis Biosyn Ltd · NSE:GUJTHEM

Gujarat Themis Biosyn — Q4 FY2022-23 Earnings Presentation

16 slides from Gujarat Themis Biosyn's earnings presentation, May 15, 2023

  1. Slide 1: Investor Presentation cover letter to BSE

    GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY : 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL : 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL: CS: BSE-CORR/2023-24 15th May, 2023 To, BSE Limited, Floor 25, Phiroze Jeejeebhoy Tower

  2. Slide 2: Result Update Presentation Q4 & FY22-23

    Gujarat Themis Biosyn Limited Result Update Presentation Q4 & FY22-23

  3. Slide 3: Disclaimer

    Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t

  4. Slide 4: Financial Highlights Q4 FY22-23 vs Q4 FY21-22

    Click to edit Master Financial title–style Highlights Q4 FY22-23 vs Q4 FY21-22 (2.05)% 14.12% 751 bps Revenue from Operations EBITDA EBITDA Margin Rs. 28.17 Crore Rs. 14.93 Crore 52.98% 19.44% 747 bps 19.44% PAT PAT Margin Basic EPS Rs. 11.69 Crore 41.50% Rs. 8.05 vs. Rs 6.74 in Q4 FY2022 3

  5. Slide 5: Quarterly Financial Highlights

    Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 44.9 47.7 28.8 28.2 28.2 18.6 Q3 FY21-22 Q4 FY21-22 Q1 FY22-23 Q2 FY22-23 Q3 FY22-23 Q4 FY22-23 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 52.7% 50.7% 51.2% 53.0% 60% 45.5% 41.5% 20 34.0% 39.5% 39.2% 45% 2

  6. Slide 6: Q4 FY22-23 Financial Highlights

    Click to Q4edit Master FY22-23 title style Financial Highlights Rs. Crs Q4 FY22-23 Q4 FY21-22 YoY% Q3 FY22-23 Income from Operations 28.17 28.76 28.17 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 28.17 28.76 (2.05%) 28.17 Cost of Materials Consumed 6.96 3.19 7.44 Changes In Inv

  7. Slide 7: Financial Highlights FY22-23 vs FY21-22

    Click to edit Master Financial title–style Highlights FY22-23 vs FY21-22 29.71% 27.86% (72 bps) Revenue from Operations EBITDA EBITDA Margin Rs. 148.97 Crore Rs. 74.22 Crore 49.82% 32.88% 93 bps 32.87% PAT PAT Margin Basic EPS Rs. 57.97 Crore 38.91% Rs. 39.90 vs. Rs 30.03 in FY2022 6

  8. Slide 8: Annual Financial Highlights

    Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 148.97 114.85 85.12 90.56 41.05 FY18-19 FY19-20 FY2021 FY21-22 FY22-23 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 80 49.8% 60% 50.5% 70 70 38.9% 45% 44.5% 50% 38.0% 60 37.4% 60 33.3% 40% 27.8% 35% 40% 50 58.0 50

  9. Slide 9: Annual Financial Highlights FY22-23

    Click to edit Master Annual Financialtitle style – FY22-23 Highlights Rs. Crs FY22-23 FY21-22 YoY% Income from Operations 148.97 114.85 Other Operating Income 0.00 0.00 Total Income from Operations 148.97 114.85 29.71% Cost of Materials Consumed 29.73 21.75 Changes In Inventory (3.24) (5.13) Employe

  10. Slide 10: Balance Sheet Highlights as on 31st March 2023

    Click to edit Master Balance title style– As on 31st March 2023 Sheet Highlights Rs. Cr. Rs. Cr. Mar 2023 Mar 2022 Mar 2023 Mar 2022 Total Equity & Liabilities Total Assets Shareholders Funds 149.15 103.32 Non Current Assets 105.48 44.11 Share Capital 7.26 7.26 32.21 18.22 Property Plant & Equipment

  11. Slide 11: Key Balance Sheet Ratios

    Click to Keyedit Master Balance title Sheet style Ratios RoCE(%)* RoA(%)** 37.0% 35.6% 34.9% 70.91% 34.2% 59.9% 57.9% 52.1% 19.6% 33.94% FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 RoE(%)*** 56.1% 43.2% 42.2% 38.9% 34.6% FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 ***

  12. Slide 12: Among India's few fermentation based intermediate manufacturers

    Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility  Incorporated in 1981 as joint  Plant in Vapi (Gujarat) sector Company with GIIC

  13. Slide 13: Product Portfolio – Growing at a fast pace

    Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin  An intermediate for Rifamycin S  An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t

  14. Slide 14: State of Art Manufacturing Facilities at Vapi

    Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 13

  15. Slide 15: Our Way Ahead

    Click to Ouredit Way Master Aheadtitle style  In process of identifying new products which have good domestic and export New Product Development & potential  Company working on strategy to move up the value chain by way of forward Forward Integration integration into API  New infrastructure being

  16. Slide 16: Thank You

    Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Bridge Investor Relations Pvt. Ltd. Mr. Sangameshwar Iyer Ms. Savli Mangle - 9833361003 Mr. Rahul Trivedi - 9833541841 sangameshwar.iyer@themismedi

Gujarat Themis Biosyn — Q4 FY2022-23 Earnings Presentation on 6ix